For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Somatostatin analogues stop your body from making too many hormones. They can reduce the symptoms of carcinoid syndrome and may slow down tumour growth.
Scope of the Report:
This report focuses on the Somatostatin Analogs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Somatostatin is a protein made naturally in the body. It is made by: a gland in the brain (hypothalamus), the stomach, the pancreas and the bowel. Somatostatin can slow down hormone production, including many of the gut hormones, slows down the emptying of the stomach and bowel, controls the release of hormones made by the pancreas, including insulin and, slows down or stops the release of growth hormones. Rise in the research and development and launch of novel drug therapies are the factors driving the growth of somatostatin analogs over the forecast period.
The worldwide market for Somatostatin Analogs is expected to grow at a CAGR of roughly 4.9% over the next five years, will reach 3230 million US$ in 2023, from 2430 million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
- Novartis
- Peptron
- Chiasma
- Ipsen Biopharmaceutical
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Octreotide
- Lanreotide
- Pasireotide
Market Segment by Applications, can be divided into
- Acromegaly
- Carcinoid Syndrome
- Neuroendocrine Tumor
- Cushing Syndrome
- Others
There are 15 Chapters to deeply display the global Somatostatin Analogs market.
Chapter 1, to describe Somatostatin Analogs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Somatostatin Analogs, with sales, revenue, and price of Somatostatin Analogs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Somatostatin Analogs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Somatostatin Analogs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Somatostatin Analogs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source